sustain adequate responses to their first TNFi have not been reported, and the recommendations are based on the panel's consideration of indirect comparisons among the available treatment options (see Supplementary Appendix 6, at http:// onlin The panel judged that treatment should differ for patients who had a primary nonresponse to TNFi and those with secondary nonresponse to TNFi. Switching to secukinumab or ixekizumab was recommended in most patients who had a primary nonresponse to the